Company intelligence / Profile preview

Toku Eyes

San Diego, California, United Statestokueyes.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Toku Eyes’ AI-driven retinal imaging tools have demonstrated the ability to non-invasively assess cardiovascular and kidney disease risks as well as estimate biological age from a single eye scan. Their CLAiR platform received FDA Breakthrough Device designation in late 2023 and CE/UKCA marks in 2024. MyKidneyAI also received FDA Breakthrough status in 2024. The company’s technology aims to make early diagnosis of systemic diseases accessible via routine eye exams

Therapeutic areas: NephrologyCardiovascularOther
Modalities: DeviceArtificial intelligence software (AI-powered diagnostic tool)
Industry: Medical Imaging

Partnerships

National Vision Inc.Topcon HealthcareEyeCheqUnified-Imaging

Beyond the preview

Go deeper on Toku Eyes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toku Eyes.

Explore the full profile